Ocugen (OCGN) Net Cash Flow (2014 - 2026)
Ocugen's (OCGN) quarterly Net Cash Flow came in at $13.2 million in Q1 2026, up 163.68% YoY from $5.0 million in Q1 2025, and up 194.21% on a QoQ basis from -$14.0 million in Q4 2025.
Analysis
Ocugen (OCGN) Net Cash Flow (2014 - 2026) Analysis & Trends
Ocugen (OCGN) has 13 years of Net Cash Flow data on file, last reported at $13.2 million in Q1 2026.
- Quarterly Net Cash Flow rose 163.68% year-over-year to $13.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.1 million (down 151.7% YoY) and the FY2025 annual result came in at -$39.9 million, down 306.65% from the prior year.
- Net Cash Flow advanced to $13.2 million in Q1 2026, from -$14.0 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $34.8 million in Q1 2022 to a low of -$24.0 million in Q4 2022.
- A 5-year average of -$3.7 million and a median of -$10.8 million in 2025 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 241.31% in 2024, down 547.18% in 2024.
- Tracing OCGN's Net Cash Flow over 5 years: stood at -$24.0 million in 2022, then soared by 41.72% to -$14.0 million in 2023, then jumped by 241.31% to $19.8 million in 2024, then plunged by 170.69% to -$14.0 million in 2025, then soared by 194.21% to $13.2 million in 2026.
- The last three Net Cash Flow figures came in at $13.2 million (Q1 2026), -$14.0 million (Q4 2025), and $5.5 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -183.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 374.50 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 407.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -496,000.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 225.59 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Ocugen | 458.91 Mn | 358.81 Mn | - | 68.15 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 68.15 Mn |
| Mar 31, 2026 | 13.18 Mn |
| Dec 31, 2025 | -13.99 Mn |
| Sep 30, 2025 | 5.51 Mn |
| Jun 30, 2025 | -10.76 Mn |
| Mar 31, 2025 | -20.70 Mn |
| Dec 31, 2024 | 19.80 Mn |
| Sep 30, 2024 | 23.01 Mn |
| Jun 30, 2024 | -10.38 Mn |
| Mar 31, 2024 | -13.09 Mn |
| Dec 31, 2023 | -14.01 Mn |
| Sep 30, 2023 | -17.11 Mn |
| Jun 30, 2023 | 2.32 Mn |
| Mar 31, 2023 | -9.30 Mn |
| Dec 31, 2022 | -24.03 Mn |
| Sep 30, 2022 | -13.42 Mn |
| Jun 30, 2022 | -14.93 Mn |
| Mar 31, 2022 | 34.81 Mn |
| Dec 31, 2021 | -12.39 Mn |
| Sep 30, 2021 | -8.29 Mn |